Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 50,397 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Clear all

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2041
U.S. locations: 424
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more

Conditions: Human Papilloma Virus (HPV) Vaccine
Interventions: HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lung Diseases, Cancer
Interventions: L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer
Interventions: ADCT-301, Pembrolizumab; Drug · Biological
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan

Conditions: Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
Interventions: IOV-5001; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor Malignancies
Interventions: ASA404, DMXAA, DXAA; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 2
States / cities: Houston, Texas • Madison, Wisconsin

Conditions: Esophageal Cancer, Gastroesophageal Junction Cancer
Interventions: Sorafenib, administered orally, CT/MRI; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma, Glioma
Interventions: GDC-0084; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim; Biological
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Acute Myeloid Leukemia
Interventions: BL-8040, Atezolizumab; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 60 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Houston, Texas • Milwaukee, Wisconsin

Conditions: Prostate Cancer
Interventions: Endomicroscopy; Device
Lead sponsor: Peter Delaney; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Lymphoma, Mantle-cell, CLL (Chronic Lymphocytic Leukemia), Monoclonal B-Cell Lymphocytosis, Healthy Volunteers, Small Lymphocytic Lymphoma
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: Paclitaxel, Pemetrexed, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Carcinoma, Renal Cell
Interventions: ABT-510/Thrombospondin-1 mimetic; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 17
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Prostatic Neoplasms
Interventions: Ketaconazole, Docetaxel; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
Interventions: sodium thiosulfate, examination; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Cancer of the Urinary Tract
Interventions: Lymph Node Dissection; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: High Grade Meningioma, Ependymoma, Medulloblastoma, PNET, Primary CNS Sarcoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer
Interventions: Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Stereotactic Body Radiotherapy (SBRT); Radiation · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: monoclonal antibody muJ591; Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Interventions: CARES Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Glioblastoma
Interventions: Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF; Biological
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)

Pharmacology Study of Aerosolized Liposomal

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

A Study of IOV-5001 in Adults With Advanced Solid Tumors

A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery

A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection

Rare CNS Tumors Outcomes &Risk

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Improving Care for Rural Patients With Solid Tumors

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.